drugset / Trial / NCT03885154

Valproic Acid and Dihydroergotamine as Abortive Therapy in Pediatric Migraine

NCT03885154

Phase 2 Terminated 24 enrolled Kimberly S Jones
RandomizedCrossoverOpen-labelTreatment

Summary

The objective of this study is to compare clinical efficacy and tolerability of valproic acid (VPA) therapy versus dihydroergotamine (DHE) as abortive therapy in pediatric migraine.

Timeline

Start
2017-10-03
Primary completion
2019-03-19
Completion
2019-03-19

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dihydroergotamine Small molecule
Comparator Valproic Acid Small molecule 1 mg/kg Intravenous

Indications